Zastaprazan

Phase 3Small molecule

Zastaprazan is one of 72 small molecule programs targeting Acute Myocardial Infarction (AMI). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myocardial Infarction (AMI)Recruiting

Ischemic StrokeNot yet recruiting

Gastroesophageal Reflux DiseaseRecruiting

Percutaneous Coronary InterventionNot yet recruiting

Acute Myocardial Infarction (AMI)Phase 3

Recruiting

Ischemic StrokePhase 3

Not yet recruiting

Gastroesophageal Reflux DiseasePhase 3

Recruiting

Percutaneous Coronary InterventionPhase 3

Not yet recruiting

Competition

Competitive Landscape

119 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Tnkase

Roche

Phase 3

17 2

Ozempic

Novo Nordisk

Phase 3

3 3

Reminyl

WWim Janssens

Phase 3

1 4

Intravenous Thrombolysis

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Phase 3

6 5

Butylphthalide

PPeking Union Medical College Hospital

Phase 3

3 6

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

1 7

Aggrastat

MMedicure

Phase 3

4 8

Zastaprazan

YYonsei University

Phase 3

1 9

Edaravone Dexborneol

SSimcere Pharmaceutical Co., Ltd

Proamatine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Post-ApprovalRecruiting

Gastroesophageal Reflux Disease

NCT07268820

Q3 2028

Post-ApprovalNot yet recruiting

Percutaneous Coronary Intervention

NCT07471867

Q3 2029

Phase 3Not yet recruiting

Ischemic Stroke

NCT07730840

Q4 2030

Phase 3Recruiting

Acute Myocardial Infarction (AMI)

NCT07467213

Clinical

Trials by Indication[1]

Gastroesophageal Reflux Disease1 trial

Heartburn, Gastroesophageal Reflux Disease

Recruiting·IIncheon St.Mary's Hospital·Phase 4·NCT07268820·160 enrolled

Percutaneous Coronary Intervention1 trial

Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention

Not yet recruiting·YYonsei University·Phase 4·NCT07471867·100 enrolled

Ischemic stroke1 trial

A Randomized, Double-Blind, Placebo-Controlled, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy of Zastaprazan in PrEventing Upper Gastrointestinal Bleeding in Patients With Transient Ischemic Attack or Ischemic Stroke Receiving Antiplatelet or Anticoagulant Therapy: ZEUS Trial

Not yet recruiting·AAsan Medical Center·Phase 3·NCT07730840·984 enrolled

Acute Myocardial Infarction (AMI)1 trial

Routine Use of Potassium Competitive Acid Blocker Versus Guideline-Directed Gastrointestinal Protection Strategy in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention on Dual Antiplatelet Therapy: A Randomized Trial

Recruiting·SSamsung Medical Center·Phase 3·NCT07467213·5,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Zastaprazan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zastaprazan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zastaprazan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: YYonsei University

Zastaprazan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2028

Q3 2029

Q4 2030

Trials by Indication[1]

Gastroesophageal Reflux Disease1 trial

Percutaneous Coronary Intervention1 trial

Ischemic stroke1 trial

Acute Myocardial Infarction (AMI)1 trial

References

Drug Info

Quick Facts

Related News